akn
Musclechemistry Member
<!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <wunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <woNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <wontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <wontVertAlignCellWithSp/> <wontBreakConstrainedForcedTables/> <wontVertAlignInTxbx/> <w:Word11KerningPairs/> <w:CachedColBalance/> <w:UseFELayout/> </w:Compatibility> <woNotOptimizeForBrowser/> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="--"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--> [FONT="]Description:[/FONT]
[FONT="]Methyltrienolone is one of the strongest oral anabolic[/FONT]
[FONT="]steroids ever produced. This agent is a derivative of[/FONT]
[FONT="]trenbolone (trienolone), which has been c-17 alpha alkylated[/FONT]
[FONT="]to allow for oral administration. This modification has[/FONT]
[FONT="]created a steroid that is significantly stronger than its nonmethylated[/FONT]
[FONT="]cousin. Its potency has been measured to be[/FONT]
[FONT="]anywhere from 120-300 times greater than that of[/FONT]
[FONT="]methyltestosterone, with greater dissociation between[/FONT]
[FONT="]anabolic and androgenic effects.535 536 Milligram for[/FONT]
[FONT="]milligram methyltrienolone is a more active steroid than any[/FONT]
[FONT="]agent sold on the commercial market, requiring doses as little[/FONT]
[FONT="]as .5-1 milligram per day to notice a strong anabolic effect.[/FONT]
[FONT="]Its potency is only matched by its relative toxicity, however,[/FONT]
[FONT="]which has limited its modern use to that of laboratory[/FONT]
[FONT="]research only.[/FONT]
[FONT="]History:[/FONT]
[FONT="]Methyltrienolone was first described in 1965.537 It was[/FONT]
[FONT="]immediately identified as an extremely potent anabolic agent,[/FONT]
[FONT="]far more potent than the commercially available agents of the[/FONT]
[FONT="]time. In spite of its high relative activity, however,[/FONT]
[FONT="]methyltrienolone has seen very limited use in humans. It was[/FONT]
[FONT="]used clinically during the late 1960’s and early ’70’s, most[/FONT]
[FONT="]notably in the treatment of advanced breast cancer. Here, its[/FONT]
[FONT="]exceedingly strong anabolic/androgenic action helps the drug[/FONT]
[FONT="]counter the local effects of endogenous estrogens, lending it[/FONT]
[FONT="]some efficacy for slowing or even regressing tumor growth.[/FONT]
[FONT="]Such application was not long lived, however, as more[/FONT]
[FONT="]realistic evaluations of the drug’s toxicity soon led to its[/FONT]
[FONT="]abandonment in human medicine.[/FONT]
[FONT="]By the mid-1970’s, methyltrienolone was becoming an[/FONT]
[FONT="]accepted standard in non-human research studies,[/FONT]
[FONT="]particularly those pertaining to the study of the androgen[/FONT]
[FONT="]receptor activity. For this purpose the agent is very well[/FONT]
[FONT="]suited. Its sheer potency and resistance to serum-binding[/FONT]
[FONT="]proteins makes it an excellent in-vitro receptor-binding[/FONT]
[FONT="]standard to compare other agents to. Being so resistant to[/FONT]
[FONT="]metabolism, active methyltrienolone metabolites are also not[/FONT]
[FONT="]going to greatly interfere with the results of most[/FONT]
[FONT="]experiments. Body tissues can metabolize most steroids[/FONT]
[FONT="]fairly easily, which means that even incubation studies can[/FONT]
[FONT="]be complicated with the question of what is causing a[/FONT]
[FONT="]particular effect, the steroid or one of its unidentified[/FONT]
[FONT="]metabolites. This is much less of an issue with[/FONT]
[FONT="]methyltrienolone. Today, methyltrienolone remains an agent[/FONT]
[FONT="]of research use only.[/FONT]
[FONT="]How Supplied:[/FONT]
[FONT="]Methyltrienolone is not available as a commercial agent.[/FONT]
[FONT="]Structural Characteristics:[/FONT]
[FONT="]Methyltrienolone is a modified form of nandrolone. It differs[/FONT]
[FONT="]by: 1) the addition of a methyl group at carbon 17- alpha to[/FONT]
[FONT="]protect the hormone during oral administration and 2) the[/FONT]
[FONT="]introduction of double bonds at carbons 9 and 11, which[/FONT]
[FONT="]increases its binding affinity and slows its metabolism. The[/FONT]
[FONT="]resulting steroid is significantly more potent than its[/FONT]
[FONT="]nandrolone base, and displays a much longer half-life and[/FONT]
[FONT="]lower affinity for serum-binding proteins in comparison.[/FONT]
[FONT="]Methyltrienolone chemically differs from trenbolone only by[/FONT]
[FONT="]the addition of a methyl group at c-17. This alteration[/FONT]
[FONT="]changes the activity of methyltrienolone considerably,[/FONT]
[FONT="]however, such that this agent should not simply be[/FONT]
[FONT="]considered an oral form of trenbolone.[/FONT]
[FONT="]Side Effects (Estrogenic):[/FONT]
[FONT="]Methyltrienolone is not aromatized by the body, and is not[/FONT]
[FONT="]measurably estrogenic. It is of note, however, that[/FONT]
[FONT="]methyltrienolone displays significant binding affinity for the[/FONT]
[FONT="]progesterone receptor.538 The side effects associated with[/FONT]
[FONT="]progesterone are similar to those of estrogen, including[/FONT]
[FONT="]negative feedback inhibition of testosterone production and[/FONT]
[FONT="]enhanced rate of fat storage. Progestins also augment the[/FONT]
[FONT="]stimulatory effect of estrogens on mammary tissue growth.[/FONT]
[FONT="]There appears to be a strong synergy between these two[/FONT]
[FONT="]hormones here, such that gynecomastia might even occur with[/FONT]
[FONT="]the help of progestins, without excessive estrogen levels. The[/FONT]
[FONT="]use of an anti-estrogen, which inhibits the estrogenic[/FONT]
[FONT="]component of this disorder, is often sufficient to mitigate[/FONT]
[FONT="]gynecomastia caused by progestational anabolic/androgenic[/FONT]
[FONT="]steroids.[/FONT]
[FONT="]Side Effects (Androgenic):[/FONT]
[FONT="]Although classified as an anabolic steroid, androgenic side[/FONT]
[FONT="]effects are still common with this substance. This may[/FONT]
[FONT="]include bouts of oily skin, acne, and body/facial hair growth.[/FONT]
[FONT="]Anabolic/androgenic steroids may also aggravate male[/FONT]
[FONT="]pattern hair loss. Women are also warned of the potential[/FONT]
[FONT="]virilizing effects of anabolic/androgenic steroids. These may[/FONT]
[FONT="]include a deepening of the voice, menstrual irregularities,[/FONT]
[FONT="]changes in skin texture, facial hair growth, and clitoral[/FONT]
[FONT="]enlargement. Additionally, the 5-alpha reductase enzyme[/FONT]
[FONT="]does not metabolize methyltrienolone, so its relative[/FONT]
[FONT="]androgenicity is not affected by finasteride or dutasteride.[/FONT]
[FONT="]Side Effects (Hepatotoxicity):[/FONT]
[FONT="]Methyltrienolone is a c17-alpha alkylated compound. This[/FONT]
[FONT="]alteration protects the drug from deactivation by the liver,[/FONT]
[FONT="]allowing a very high percentage of the drug entry into the[/FONT]
[FONT="]bloodstream following oral administration. C17-alpha[/FONT]
[FONT="]alkylated anabolic/androgenic steroids can be hepatotoxic.[/FONT]
[FONT="]Prolonged or high exposure may result in liver damage. In[/FONT]
[FONT="]rare instances life-threatening dysfunction may develop. It is[/FONT]
[FONT="]advisable to visit a physician periodically during each cycle[/FONT]
[FONT="]to monitor liver function and overall health. Intake of c17-[/FONT]
[FONT="]alpha alkylated steroids is commonly limited to 6-8 weeks,[/FONT]
[FONT="]in an effort to avoid escalating liver strain.[/FONT]
[FONT="]Methyltrienolone is an exceedingly potent oral steroid, with[/FONT]
[FONT="]a very high level of resistance to hepatic metabolism. This[/FONT]
[FONT="]makes methyltrienolone exceedingly liver-toxic, precluding[/FONT]
[FONT="]its use as a prescription agent at this time, in any part of the[/FONT]
[FONT="]world. Studies published from the University of Bonn[/FONT]
[FONT="]Germany back in 1966 make this very clear.539 In fact, at this[/FONT]
[FONT="]time researchers had deemed this the most liver-toxic steroid[/FONT]
[FONT="]to ever be studied in humans, summing up their findings well[/FONT]
[FONT="]when stating:[/FONT]
[FONT="]“Methyltrienolone… which is orally active as an anabolic[/FONT]
[FONT="]agent in a dose less than 1.0 mg per day in normal adults,has[/FONT]
[FONT="]been tested with regard to its influence on liver function. As[/FONT]
[FONT="]measured by multiple parameters (BSP retention; total[/FONT]
[FONT="]bilirubin; activities of transaminases, alkaline phosphates[/FONT]
[FONT="]and cholinesterase in serum; activity of proaccelerin in[/FONT]
[FONT="]plasma) methyltrienolone turned out to be very active as to[/FONT]
[FONT="]causing biochemical symptoms of intrahepatic cholestasis.[/FONT]
[FONT="]…thus methyltrienolone at present being the most[/FONT]
[FONT="]‘hepatotoxic’ steroid.”[/FONT]
[FONT="]The use of a liver detoxification supplement such as Liver[/FONT]
[FONT="]Stabil, Liv-52, or Essentiale Forte is advised while taking[/FONT]
[FONT="]any hepatotoxic anabolic/androgenic steroids.[/FONT]
[FONT="]Side Effects (Cardiovascular):[/FONT]
[FONT="]Anabolic/androgenic steroids can have deleterious effects on[/FONT]
[FONT="]serum cholesterol. This includes a tendency to reduce HDL[/FONT]
[FONT="](good) cholesterol values and increase LDL (bad)[/FONT]
[FONT="]cholesterol values, which may shift the HDL to LDL balance[/FONT]
[FONT="]in a direction that favors greater risk of arteriosclerosis. The[/FONT]
[FONT="]relative impact of an anabolic/androgenic steroid on serum[/FONT]
[FONT="]lipids is dependant on the dose, route of administration (oral[/FONT]
[FONT="]vs. injectable), type of steroid (aromatizable or nonaromatizable),[/FONT]
[FONT="]and level of resistance to hepatic metabolism.[/FONT]
[FONT="]Although not extensively studied in humans, the oral route,[/FONT]
[FONT="]high relative potency, and non-aromatizable nature of[/FONT]
[FONT="]methyltrienolone suggest that this agent is extremely prone to[/FONT]
[FONT="]negatively altering lipid values and increasing atherogenic[/FONT]
[FONT="]risk. Anabolic/androgenic steroids may also adversely affect[/FONT]
[FONT="]blood pressure and triglycerides, reduce endothelial[/FONT]
[FONT="]relaxation, and support left ventricular hypertrophy, all[/FONT]
[FONT="]potentially increasing the risk of cardiovascular disease and[/FONT]
[FONT="]myocardial infarction.[/FONT]
[FONT="]To help reduce cardiovascular strain it is advised to[/FONT]
[FONT="]maintain an active cardiovascular exercise program and[/FONT]
[FONT="]minimize the intake of saturated fats, cholesterol, and simple[/FONT]
[FONT="]carbohydrates at all times during active AAS administration.[/FONT]
[FONT="]Supplementing with fish oils (4 grams per day) and a natural[/FONT]
[FONT="]cholesterol/antioxidant formula such as Lipid Stabil or a[/FONT]
[FONT="]product with comparable ingredients is also recommended.[/FONT]
[FONT="]Side Effects (Testosterone Suppression):[/FONT]
[FONT="]All anabolic/androgenic steroids when taken in doses[/FONT]
[FONT="]sufficient to promote muscle gain are expected to suppress[/FONT]
[FONT="]endogenous testosterone production. Without the intervention[/FONT]
[FONT="]of testosterone-stimulating substances, testosterone levels[/FONT]
[FONT="]should return to normal within 1-4 months of drug secession.[/FONT]
[FONT="]Note that prolonged hypogonadotrophic hypogonadism can[/FONT]
[FONT="]develop secondary to steroid abuse, necessitating medical[/FONT]
[FONT="]intervention.[/FONT]
[FONT="]Administration (General):[/FONT]
[FONT="]Studies have shown that taking an oral anabolic steroid with[/FONT]
[FONT="]food may decrease its bioavailability.540 This is caused by[/FONT]
[FONT="]the fat-soluble nature of steroid hormones, which can allow[/FONT]
[FONT="]some of the drug to dissolve with undigested dietary fat,[/FONT]
[FONT="]reducing its absorption from the gastrointestinal tract. For[/FONT]
[FONT="]maximum utilization, methyltrienolone should be taken on an[/FONT]
[FONT="]empty stomach.[/FONT]
[FONT="]Administration (Men):[/FONT]
[FONT="]Methyltrienolone is no longer used in clinical medicine due[/FONT]
[FONT="]to an unacceptable level of hepatotoxicity. This agent is[/FONT]
[FONT="]generally not recommended for physique- or performance[/FONT]
[FONT="]enhancing purposes for the same reason. Those absolutely[/FONT]
[FONT="]insisting on its use need to take its level of liver toxicity very[/FONT]
[FONT="]seriously. At the very least, routine blood tests should be[/FONT]
[FONT="]conducted to ensure the agent is not imparting damage. Drug[/FONT]
[FONT="]duration should also be very limited, preferably to 4 weeks[/FONT]
[FONT="]of use or less. The relative potency of methyltrienolone is[/FONT]
[FONT="]extremely high, requiring doses as little as .5 milligram per[/FONT]
[FONT="]day. Its effective and tolerable range is usually considered to[/FONT]
[FONT="]be .5 to 2mg per day. Dianabol-type doses of 20-30 mg daily[/FONT]
[FONT="]are completely unthinkable, and should never be attempted.[/FONT]
[FONT="]Again, this is an extremely toxic steroid, and all good advice[/FONT]
[FONT="]would say to avoid it. Any one of the many commercially[/FONT]
[FONT="]available steroids would be much safer choices.[/FONT]
[FONT="]Administration (Women):[/FONT]
[FONT="]Methyltrienolone is no longer used in clinical medicine due[/FONT]
[FONT="]to an unacceptable level of hepatotoxicity. This agent is not[/FONT]
[FONT="]recommended for women for physique- or performanceenhancing[/FONT]
[FONT="]purposes due to its extremely strong toxicity and[/FONT]
[FONT="]tendency to produce virilizing side effects.[/FONT]
[FONT="]Availability:[/FONT]
[FONT="]Methyltrienolone is not produced as a prescription steroid[/FONT]
[FONT="]product in any part of the world. With the rapid expansion of[/FONT]
[FONT="]underground steroid manufacturers, this agent has been[/FONT]
[FONT="]released as a black market designer compound. Those[/FONT]
[FONT="]contemplating the use of underground forms of[/FONT]
[FONT="]methyltrienolone should consider that such agents are being[/FONT]
[FONT="]released for human use without any government approval or[/FONT]
[FONT="]consideration to its safety[/FONT][FONT="][/FONT]
<!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} </style> <![endif]-->
[FONT="]Methyltrienolone is one of the strongest oral anabolic[/FONT]
[FONT="]steroids ever produced. This agent is a derivative of[/FONT]
[FONT="]trenbolone (trienolone), which has been c-17 alpha alkylated[/FONT]
[FONT="]to allow for oral administration. This modification has[/FONT]
[FONT="]created a steroid that is significantly stronger than its nonmethylated[/FONT]
[FONT="]cousin. Its potency has been measured to be[/FONT]
[FONT="]anywhere from 120-300 times greater than that of[/FONT]
[FONT="]methyltestosterone, with greater dissociation between[/FONT]
[FONT="]anabolic and androgenic effects.535 536 Milligram for[/FONT]
[FONT="]milligram methyltrienolone is a more active steroid than any[/FONT]
[FONT="]agent sold on the commercial market, requiring doses as little[/FONT]
[FONT="]as .5-1 milligram per day to notice a strong anabolic effect.[/FONT]
[FONT="]Its potency is only matched by its relative toxicity, however,[/FONT]
[FONT="]which has limited its modern use to that of laboratory[/FONT]
[FONT="]research only.[/FONT]
[FONT="]History:[/FONT]
[FONT="]Methyltrienolone was first described in 1965.537 It was[/FONT]
[FONT="]immediately identified as an extremely potent anabolic agent,[/FONT]
[FONT="]far more potent than the commercially available agents of the[/FONT]
[FONT="]time. In spite of its high relative activity, however,[/FONT]
[FONT="]methyltrienolone has seen very limited use in humans. It was[/FONT]
[FONT="]used clinically during the late 1960’s and early ’70’s, most[/FONT]
[FONT="]notably in the treatment of advanced breast cancer. Here, its[/FONT]
[FONT="]exceedingly strong anabolic/androgenic action helps the drug[/FONT]
[FONT="]counter the local effects of endogenous estrogens, lending it[/FONT]
[FONT="]some efficacy for slowing or even regressing tumor growth.[/FONT]
[FONT="]Such application was not long lived, however, as more[/FONT]
[FONT="]realistic evaluations of the drug’s toxicity soon led to its[/FONT]
[FONT="]abandonment in human medicine.[/FONT]
[FONT="]By the mid-1970’s, methyltrienolone was becoming an[/FONT]
[FONT="]accepted standard in non-human research studies,[/FONT]
[FONT="]particularly those pertaining to the study of the androgen[/FONT]
[FONT="]receptor activity. For this purpose the agent is very well[/FONT]
[FONT="]suited. Its sheer potency and resistance to serum-binding[/FONT]
[FONT="]proteins makes it an excellent in-vitro receptor-binding[/FONT]
[FONT="]standard to compare other agents to. Being so resistant to[/FONT]
[FONT="]metabolism, active methyltrienolone metabolites are also not[/FONT]
[FONT="]going to greatly interfere with the results of most[/FONT]
[FONT="]experiments. Body tissues can metabolize most steroids[/FONT]
[FONT="]fairly easily, which means that even incubation studies can[/FONT]
[FONT="]be complicated with the question of what is causing a[/FONT]
[FONT="]particular effect, the steroid or one of its unidentified[/FONT]
[FONT="]metabolites. This is much less of an issue with[/FONT]
[FONT="]methyltrienolone. Today, methyltrienolone remains an agent[/FONT]
[FONT="]of research use only.[/FONT]
[FONT="]How Supplied:[/FONT]
[FONT="]Methyltrienolone is not available as a commercial agent.[/FONT]
[FONT="]Structural Characteristics:[/FONT]
[FONT="]Methyltrienolone is a modified form of nandrolone. It differs[/FONT]
[FONT="]by: 1) the addition of a methyl group at carbon 17- alpha to[/FONT]
[FONT="]protect the hormone during oral administration and 2) the[/FONT]
[FONT="]introduction of double bonds at carbons 9 and 11, which[/FONT]
[FONT="]increases its binding affinity and slows its metabolism. The[/FONT]
[FONT="]resulting steroid is significantly more potent than its[/FONT]
[FONT="]nandrolone base, and displays a much longer half-life and[/FONT]
[FONT="]lower affinity for serum-binding proteins in comparison.[/FONT]
[FONT="]Methyltrienolone chemically differs from trenbolone only by[/FONT]
[FONT="]the addition of a methyl group at c-17. This alteration[/FONT]
[FONT="]changes the activity of methyltrienolone considerably,[/FONT]
[FONT="]however, such that this agent should not simply be[/FONT]
[FONT="]considered an oral form of trenbolone.[/FONT]
[FONT="]Side Effects (Estrogenic):[/FONT]
[FONT="]Methyltrienolone is not aromatized by the body, and is not[/FONT]
[FONT="]measurably estrogenic. It is of note, however, that[/FONT]
[FONT="]methyltrienolone displays significant binding affinity for the[/FONT]
[FONT="]progesterone receptor.538 The side effects associated with[/FONT]
[FONT="]progesterone are similar to those of estrogen, including[/FONT]
[FONT="]negative feedback inhibition of testosterone production and[/FONT]
[FONT="]enhanced rate of fat storage. Progestins also augment the[/FONT]
[FONT="]stimulatory effect of estrogens on mammary tissue growth.[/FONT]
[FONT="]There appears to be a strong synergy between these two[/FONT]
[FONT="]hormones here, such that gynecomastia might even occur with[/FONT]
[FONT="]the help of progestins, without excessive estrogen levels. The[/FONT]
[FONT="]use of an anti-estrogen, which inhibits the estrogenic[/FONT]
[FONT="]component of this disorder, is often sufficient to mitigate[/FONT]
[FONT="]gynecomastia caused by progestational anabolic/androgenic[/FONT]
[FONT="]steroids.[/FONT]
[FONT="]Side Effects (Androgenic):[/FONT]
[FONT="]Although classified as an anabolic steroid, androgenic side[/FONT]
[FONT="]effects are still common with this substance. This may[/FONT]
[FONT="]include bouts of oily skin, acne, and body/facial hair growth.[/FONT]
[FONT="]Anabolic/androgenic steroids may also aggravate male[/FONT]
[FONT="]pattern hair loss. Women are also warned of the potential[/FONT]
[FONT="]virilizing effects of anabolic/androgenic steroids. These may[/FONT]
[FONT="]include a deepening of the voice, menstrual irregularities,[/FONT]
[FONT="]changes in skin texture, facial hair growth, and clitoral[/FONT]
[FONT="]enlargement. Additionally, the 5-alpha reductase enzyme[/FONT]
[FONT="]does not metabolize methyltrienolone, so its relative[/FONT]
[FONT="]androgenicity is not affected by finasteride or dutasteride.[/FONT]
[FONT="]Side Effects (Hepatotoxicity):[/FONT]
[FONT="]Methyltrienolone is a c17-alpha alkylated compound. This[/FONT]
[FONT="]alteration protects the drug from deactivation by the liver,[/FONT]
[FONT="]allowing a very high percentage of the drug entry into the[/FONT]
[FONT="]bloodstream following oral administration. C17-alpha[/FONT]
[FONT="]alkylated anabolic/androgenic steroids can be hepatotoxic.[/FONT]
[FONT="]Prolonged or high exposure may result in liver damage. In[/FONT]
[FONT="]rare instances life-threatening dysfunction may develop. It is[/FONT]
[FONT="]advisable to visit a physician periodically during each cycle[/FONT]
[FONT="]to monitor liver function and overall health. Intake of c17-[/FONT]
[FONT="]alpha alkylated steroids is commonly limited to 6-8 weeks,[/FONT]
[FONT="]in an effort to avoid escalating liver strain.[/FONT]
[FONT="]Methyltrienolone is an exceedingly potent oral steroid, with[/FONT]
[FONT="]a very high level of resistance to hepatic metabolism. This[/FONT]
[FONT="]makes methyltrienolone exceedingly liver-toxic, precluding[/FONT]
[FONT="]its use as a prescription agent at this time, in any part of the[/FONT]
[FONT="]world. Studies published from the University of Bonn[/FONT]
[FONT="]Germany back in 1966 make this very clear.539 In fact, at this[/FONT]
[FONT="]time researchers had deemed this the most liver-toxic steroid[/FONT]
[FONT="]to ever be studied in humans, summing up their findings well[/FONT]
[FONT="]when stating:[/FONT]
[FONT="]“Methyltrienolone… which is orally active as an anabolic[/FONT]
[FONT="]agent in a dose less than 1.0 mg per day in normal adults,has[/FONT]
[FONT="]been tested with regard to its influence on liver function. As[/FONT]
[FONT="]measured by multiple parameters (BSP retention; total[/FONT]
[FONT="]bilirubin; activities of transaminases, alkaline phosphates[/FONT]
[FONT="]and cholinesterase in serum; activity of proaccelerin in[/FONT]
[FONT="]plasma) methyltrienolone turned out to be very active as to[/FONT]
[FONT="]causing biochemical symptoms of intrahepatic cholestasis.[/FONT]
[FONT="]…thus methyltrienolone at present being the most[/FONT]
[FONT="]‘hepatotoxic’ steroid.”[/FONT]
[FONT="]The use of a liver detoxification supplement such as Liver[/FONT]
[FONT="]Stabil, Liv-52, or Essentiale Forte is advised while taking[/FONT]
[FONT="]any hepatotoxic anabolic/androgenic steroids.[/FONT]
[FONT="]Side Effects (Cardiovascular):[/FONT]
[FONT="]Anabolic/androgenic steroids can have deleterious effects on[/FONT]
[FONT="]serum cholesterol. This includes a tendency to reduce HDL[/FONT]
[FONT="](good) cholesterol values and increase LDL (bad)[/FONT]
[FONT="]cholesterol values, which may shift the HDL to LDL balance[/FONT]
[FONT="]in a direction that favors greater risk of arteriosclerosis. The[/FONT]
[FONT="]relative impact of an anabolic/androgenic steroid on serum[/FONT]
[FONT="]lipids is dependant on the dose, route of administration (oral[/FONT]
[FONT="]vs. injectable), type of steroid (aromatizable or nonaromatizable),[/FONT]
[FONT="]and level of resistance to hepatic metabolism.[/FONT]
[FONT="]Although not extensively studied in humans, the oral route,[/FONT]
[FONT="]high relative potency, and non-aromatizable nature of[/FONT]
[FONT="]methyltrienolone suggest that this agent is extremely prone to[/FONT]
[FONT="]negatively altering lipid values and increasing atherogenic[/FONT]
[FONT="]risk. Anabolic/androgenic steroids may also adversely affect[/FONT]
[FONT="]blood pressure and triglycerides, reduce endothelial[/FONT]
[FONT="]relaxation, and support left ventricular hypertrophy, all[/FONT]
[FONT="]potentially increasing the risk of cardiovascular disease and[/FONT]
[FONT="]myocardial infarction.[/FONT]
[FONT="]To help reduce cardiovascular strain it is advised to[/FONT]
[FONT="]maintain an active cardiovascular exercise program and[/FONT]
[FONT="]minimize the intake of saturated fats, cholesterol, and simple[/FONT]
[FONT="]carbohydrates at all times during active AAS administration.[/FONT]
[FONT="]Supplementing with fish oils (4 grams per day) and a natural[/FONT]
[FONT="]cholesterol/antioxidant formula such as Lipid Stabil or a[/FONT]
[FONT="]product with comparable ingredients is also recommended.[/FONT]
[FONT="]Side Effects (Testosterone Suppression):[/FONT]
[FONT="]All anabolic/androgenic steroids when taken in doses[/FONT]
[FONT="]sufficient to promote muscle gain are expected to suppress[/FONT]
[FONT="]endogenous testosterone production. Without the intervention[/FONT]
[FONT="]of testosterone-stimulating substances, testosterone levels[/FONT]
[FONT="]should return to normal within 1-4 months of drug secession.[/FONT]
[FONT="]Note that prolonged hypogonadotrophic hypogonadism can[/FONT]
[FONT="]develop secondary to steroid abuse, necessitating medical[/FONT]
[FONT="]intervention.[/FONT]
[FONT="]Administration (General):[/FONT]
[FONT="]Studies have shown that taking an oral anabolic steroid with[/FONT]
[FONT="]food may decrease its bioavailability.540 This is caused by[/FONT]
[FONT="]the fat-soluble nature of steroid hormones, which can allow[/FONT]
[FONT="]some of the drug to dissolve with undigested dietary fat,[/FONT]
[FONT="]reducing its absorption from the gastrointestinal tract. For[/FONT]
[FONT="]maximum utilization, methyltrienolone should be taken on an[/FONT]
[FONT="]empty stomach.[/FONT]
[FONT="]Administration (Men):[/FONT]
[FONT="]Methyltrienolone is no longer used in clinical medicine due[/FONT]
[FONT="]to an unacceptable level of hepatotoxicity. This agent is[/FONT]
[FONT="]generally not recommended for physique- or performance[/FONT]
[FONT="]enhancing purposes for the same reason. Those absolutely[/FONT]
[FONT="]insisting on its use need to take its level of liver toxicity very[/FONT]
[FONT="]seriously. At the very least, routine blood tests should be[/FONT]
[FONT="]conducted to ensure the agent is not imparting damage. Drug[/FONT]
[FONT="]duration should also be very limited, preferably to 4 weeks[/FONT]
[FONT="]of use or less. The relative potency of methyltrienolone is[/FONT]
[FONT="]extremely high, requiring doses as little as .5 milligram per[/FONT]
[FONT="]day. Its effective and tolerable range is usually considered to[/FONT]
[FONT="]be .5 to 2mg per day. Dianabol-type doses of 20-30 mg daily[/FONT]
[FONT="]are completely unthinkable, and should never be attempted.[/FONT]
[FONT="]Again, this is an extremely toxic steroid, and all good advice[/FONT]
[FONT="]would say to avoid it. Any one of the many commercially[/FONT]
[FONT="]available steroids would be much safer choices.[/FONT]
[FONT="]Administration (Women):[/FONT]
[FONT="]Methyltrienolone is no longer used in clinical medicine due[/FONT]
[FONT="]to an unacceptable level of hepatotoxicity. This agent is not[/FONT]
[FONT="]recommended for women for physique- or performanceenhancing[/FONT]
[FONT="]purposes due to its extremely strong toxicity and[/FONT]
[FONT="]tendency to produce virilizing side effects.[/FONT]
[FONT="]Availability:[/FONT]
[FONT="]Methyltrienolone is not produced as a prescription steroid[/FONT]
[FONT="]product in any part of the world. With the rapid expansion of[/FONT]
[FONT="]underground steroid manufacturers, this agent has been[/FONT]
[FONT="]released as a black market designer compound. Those[/FONT]
[FONT="]contemplating the use of underground forms of[/FONT]
[FONT="]methyltrienolone should consider that such agents are being[/FONT]
[FONT="]released for human use without any government approval or[/FONT]
[FONT="]consideration to its safety[/FONT][FONT="][/FONT]
<!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} </style> <![endif]-->